Browsing Category
Healthcare Industry News
2510 posts
SIR 2026 annual scientific meeting: what interventional radiologists need to know about Toronto
SIR 2026 runs April 11-15 at the Metro Toronto Convention Centre. Over 4,000 IR professionals, 400+ presentations, robotics, ablation and AI sessions covered.
Penumbra (NYSE: PEN) says STORM-PE 90-day data strengthens case for thrombectomy in pulmonary embolism
Penumbra’s new STORM-PE data showed stronger 90-day recovery in pulmonary embolism patients. Read what it means for growth, competition, and care.
Glaukos at ASCRS 2026: Epioxa commercial launch and the growing case for interventional eye care
Glaukos presents Epioxa and iDose TR data at ASCRS 2026. Full coverage of the keratoconus launch, glaucoma pipeline, Q4 results, and 2026 revenue guidance for NYSE: GKOS.
Prader-Willi syndrome: What families need to know about causes, care, and the treatment breakthrough that just changed everything
Prader-Willi syndrome explained for families and carers: causes, diagnosis, care, the 2025 FDA approval of Vykat XR, and what the latest trials mean for treatment.
AI in ophthalmology at ASCRS 2026: What the Washington DC meeting is signalling about the specialty’s technology future
Kerry Solomon's Binkhorst Lecture at ASCRS 2026 in Washington DC puts AI at the centre of ophthalmology. Coverage of Zeiss VisioGen, IOL calculators, and Sean Ianchulev's Kelman Lecture.
Johnson & Johnson shows new TECNIS PureSee data at ASCRS 2026 as JNJ eyes deeper ophthalmology upside
Johnson & Johnson unveiled new TECNIS PureSee data at ASCRS 2026. Read how it could reshape cataract surgery growth and JNJ’s medtech outlook.
Ovarian cancer treatment options, survival rates, and the newest FDA approvals in 2026
Ovarian cancer affects 21,000 US women annually. This guide covers symptoms, staging, survival rates, BRCA risk, and the newest FDA-approved treatments through early 2026.
Unilever to buy U.S. greens supplement company Grüns in latest wellbeing push
Unilever has agreed to acquire U.S. greens supplement brand Grüns in a deal valuing the three-year-old company at around $500 million. Read what it means for UL investors and the VMS market.
Why Four Corners Property Trust’s $4.4m National Veterinary Associates deal matters more than its size suggests
Four Corners Property Trust bought a National Veterinary Associates property for $4.4 million. Read why this small deal could matter for FCPT’s 2026 strategy.
Abbott hit with $70m Illinois verdict in premature infant formula case
Illinois jury awards $70 million against Abbott in a premature infant NEC formula case. Read what the Cook County verdict means now.